BACKGROUND: Familial Mediterranean fever (FMF) patients suffer from chronic complications of disease such as AA amyloidosis, chronic arthritis, and spondylitis. Reduced quality of life (QoL) is a feature of chronic diseases but it is also impaired in patients with FMF. Despite the regular use of colchicine at a maximal dose, about 10% of patients do not respond well or resistant to colchicine (crFMF). IL-1 inhibitors have been shown to be effective in controlling attacks in crFMF patients. Herein, we aimed to investigate QoL changes of crFMF patients with IL-1 inhibitors. METHODS: All patients were prospectively monitored for the frequency, duration, severity of attacks, patient global assessments (Visual Analog Scale; VAS), and laboratory features. Either anakinra or canakinumab was used as IL-1 antagonist treatments. Demographic information, MEFV gene mutations, attack characteristics, and previous treatments were registered. Short form-36 (SF-36) quality of life scale was implemented by the interviewer for evaluating the QoL before and 3 months after the treatment. RESULTS: A total of 44 patients were included in this study. Striking improvements were detected in frequency, duration, and VAS severity of attacks (p < 0.001). In the comparison of pre- and post-treatment, SF-36 sub-components significant improvements were observed on physical function, role limitation due to physical difficulty, role limitation due to emotional problem, energy, emotional well-being, social function, pain, general health, and health change. CONCLUSIONS: In conclusion, IL-1 antagonists prevent attacks and improve QoL of crFMF.
BACKGROUND:Familial Mediterranean fever (FMF) patients suffer from chronic complications of disease such as AA amyloidosis, chronic arthritis, and spondylitis. Reduced quality of life (QoL) is a feature of chronic diseases but it is also impaired in patients with FMF. Despite the regular use of colchicine at a maximal dose, about 10% of patients do not respond well or resistant to colchicine (crFMF). IL-1 inhibitors have been shown to be effective in controlling attacks in crFMFpatients. Herein, we aimed to investigate QoL changes of crFMFpatients with IL-1 inhibitors. METHODS: All patients were prospectively monitored for the frequency, duration, severity of attacks, patient global assessments (Visual Analog Scale; VAS), and laboratory features. Either anakinra or canakinumab was used as IL-1 antagonist treatments. Demographic information, MEFV gene mutations, attack characteristics, and previous treatments were registered. Short form-36 (SF-36) quality of life scale was implemented by the interviewer for evaluating the QoL before and 3 months after the treatment. RESULTS: A total of 44 patients were included in this study. Striking improvements were detected in frequency, duration, and VAS severity of attacks (p < 0.001). In the comparison of pre- and post-treatment, SF-36 sub-components significant improvements were observed on physical function, role limitation due to physical difficulty, role limitation due to emotional problem, energy, emotional well-being, social function, pain, general health, and health change. CONCLUSIONS: In conclusion, IL-1 antagonists prevent attacks and improve QoL of crFMF.
Entities:
Keywords:
Anakinra; Canakinumab; Familial Mediterranean fever; IL-1 antagonist; Quality of life
Authors: Arnd Giese; Mustafa Kurucay; Levent Kilic; Ahmet Örnek; Süleyman Nahit Şendur; Elke Lainka; Bernhard Ferdinand Henning Journal: Rheumatol Int Date: 2012-12-29 Impact factor: 2.631
Authors: Philip J Hashkes; Steven J Spalding; Rula Hajj-Ali; Edward H Giannini; Anne Johnson; Karyl S Barron; Michael H Weisman; Noune Pashinian; Andreas O Reiff; Jonathan Samuels; Dowain Wright; Daniel J Lovell; Bin Huang Journal: Biomed Res Int Date: 2014-05-15 Impact factor: 3.411
Authors: Eliana Shaul; Máire A Conrad; Noor Dawany; Trusha Patel; Megan C Canavan; Alyssa Baccarella; Sarah Weinbrom; Daniel Aleynick; Kathleen E Sullivan; Judith R Kelsen Journal: Front Immunol Date: 2022-09-20 Impact factor: 8.786